I'm not sure the impact of the BLA. On one hand, it should be price in by now, but you could also argue that we have already retreated from highs due in part to missing deadlines for submitting. We could go back to some higher level if it is submitted.
It is also quite possible that financing will follow closely behind the BLA. There is some chance out there that we have a deal contingent on getting it submitted. Nader didn't admit as much when going through the offers a few weeks back, but it makes some sense. Not saying this is likely, but certainly plausible.

I say it every week amidst all of the other noise, but financing/licensing and the BTD are the only things that can push us to the $2 price for uplisting. Coronavirus trials, cancer reports, NASH, MS, GVHD, etc. do not matter to the short term financial outlook. Good news is nice to hear, but unless the FDA validates the data, we have shown that a simple PR won't move/sustain increased pricing.